Global AI-driven Drug Discovery 麻豆原创 Research Report 2024

Publication ID:

PB507245833

Publication Date:

July 2, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

AI, its end-to-end drug discovery platform using generative artificial intelligence to discover new targets, design new molecules, and predict the outcome of clinical trials.
The global AI-driven Drug Discovery market was valued at US$ 716 million in 2023 and is anticipated to reach US$ 1372.6 million by 2030, witnessing a CAGR of 10.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for AI-driven Drug Discovery, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding AI-driven Drug Discovery.
Report Scope
The AI-driven Drug Discovery market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global AI-driven Drug Discovery market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the AI-driven Drug Discovery companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Entos
Selvita
Benevolent
Exscientia
Euretos
Illumina with AstraZeneca
Novo Nordisk with Microsoft
Iktos
Aqemia
Zephyr AI
Cyclicarx
Eli Lilly
Terray Therapeutics
Ardigen
ReviveMed
Insilico Medicine
XtalPi
MindRank
DP Technology
Segment by Type
Small Molecule Drug
Biological Modeling
Structural Biology
Others
Segment by Application
Pharmaceutical and Biotechnology Companies
Research Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of AI-driven Drug Discovery companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global AI-driven Drug Discovery 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Small Molecule Drug
1.2.3 Biological Modeling
1.2.4 Structural Biology
1.2.5 Others
1.3 麻豆原创 by Application
1.3.1 Global AI-driven Drug Discovery 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Research Laboratories
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global AI-driven Drug Discovery 麻豆原创 Perspective (2019-2030)
2.2 AI-driven Drug Discovery Growth Trends by Region
2.2.1 Global AI-driven Drug Discovery 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 AI-driven Drug Discovery Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 AI-driven Drug Discovery Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 AI-driven Drug Discovery 麻豆原创 Dynamics
2.3.1 AI-driven Drug Discovery Industry Trends
2.3.2 AI-driven Drug Discovery 麻豆原创 Drivers
2.3.3 AI-driven Drug Discovery 麻豆原创 Challenges
2.3.4 AI-driven Drug Discovery 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top AI-driven Drug Discovery Players by Revenue
3.1.1 Global Top AI-driven Drug Discovery Players by Revenue (2019-2024)
3.1.2 Global AI-driven Drug Discovery Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global AI-driven Drug Discovery 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by AI-driven Drug Discovery Revenue
3.4 Global AI-driven Drug Discovery 麻豆原创 Concentration Ratio
3.4.1 Global AI-driven Drug Discovery 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by AI-driven Drug Discovery Revenue in 2023
3.5 AI-driven Drug Discovery Key Players Head office and Area Served
3.6 Key Players AI-driven Drug Discovery Product Solution and Service
3.7 Date of Enter into AI-driven Drug Discovery 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 AI-driven Drug Discovery Breakdown Data by Type
4.1 Global AI-driven Drug Discovery Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global AI-driven Drug Discovery Forecasted 麻豆原创 Size by Type (2025-2030)
5 AI-driven Drug Discovery Breakdown Data by Application
5.1 Global AI-driven Drug Discovery Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global AI-driven Drug Discovery Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America AI-driven Drug Discovery 麻豆原创 Size (2019-2030)
6.2 North America AI-driven Drug Discovery 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America AI-driven Drug Discovery 麻豆原创 Size by Country (2019-2024)
6.4 North America AI-driven Drug Discovery 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe AI-driven Drug Discovery 麻豆原创 Size (2019-2030)
7.2 Europe AI-driven Drug Discovery 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe AI-driven Drug Discovery 麻豆原创 Size by Country (2019-2024)
7.4 Europe AI-driven Drug Discovery 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific AI-driven Drug Discovery 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific AI-driven Drug Discovery 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific AI-driven Drug Discovery 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific AI-driven Drug Discovery 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America AI-driven Drug Discovery 麻豆原创 Size (2019-2030)
9.2 Latin America AI-driven Drug Discovery 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America AI-driven Drug Discovery 麻豆原创 Size by Country (2019-2024)
9.4 Latin America AI-driven Drug Discovery 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa AI-driven Drug Discovery 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa AI-driven Drug Discovery 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa AI-driven Drug Discovery 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa AI-driven Drug Discovery 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Entos
11.1.1 Entos Company Detail
11.1.2 Entos Business Overview
11.1.3 Entos AI-driven Drug Discovery Introduction
11.1.4 Entos Revenue in AI-driven Drug Discovery Business (2019-2024)
11.1.5 Entos Recent Development
11.2 Selvita
11.2.1 Selvita Company Detail
11.2.2 Selvita Business Overview
11.2.3 Selvita AI-driven Drug Discovery Introduction
11.2.4 Selvita Revenue in AI-driven Drug Discovery Business (2019-2024)
11.2.5 Selvita Recent Development
11.3 Benevolent
11.3.1 Benevolent Company Detail
11.3.2 Benevolent Business Overview
11.3.3 Benevolent AI-driven Drug Discovery Introduction
11.3.4 Benevolent Revenue in AI-driven Drug Discovery Business (2019-2024)
11.3.5 Benevolent Recent Development
11.4 Exscientia
11.4.1 Exscientia Company Detail
11.4.2 Exscientia Business Overview
11.4.3 Exscientia AI-driven Drug Discovery Introduction
11.4.4 Exscientia Revenue in AI-driven Drug Discovery Business (2019-2024)
11.4.5 Exscientia Recent Development
11.5 Euretos
11.5.1 Euretos Company Detail
11.5.2 Euretos Business Overview
11.5.3 Euretos AI-driven Drug Discovery Introduction
11.5.4 Euretos Revenue in AI-driven Drug Discovery Business (2019-2024)
11.5.5 Euretos Recent Development
11.6 Illumina with AstraZeneca
11.6.1 Illumina with AstraZeneca Company Detail
11.6.2 Illumina with AstraZeneca Business Overview
11.6.3 Illumina with AstraZeneca AI-driven Drug Discovery Introduction
11.6.4 Illumina with AstraZeneca Revenue in AI-driven Drug Discovery Business (2019-2024)
11.6.5 Illumina with AstraZeneca Recent Development
11.7 Novo Nordisk with Microsoft
11.7.1 Novo Nordisk with Microsoft Company Detail
11.7.2 Novo Nordisk with Microsoft Business Overview
11.7.3 Novo Nordisk with Microsoft AI-driven Drug Discovery Introduction
11.7.4 Novo Nordisk with Microsoft Revenue in AI-driven Drug Discovery Business (2019-2024)
11.7.5 Novo Nordisk with Microsoft Recent Development
11.8 Iktos
11.8.1 Iktos Company Detail
11.8.2 Iktos Business Overview
11.8.3 Iktos AI-driven Drug Discovery Introduction
11.8.4 Iktos Revenue in AI-driven Drug Discovery Business (2019-2024)
11.8.5 Iktos Recent Development
11.9 Aqemia
11.9.1 Aqemia Company Detail
11.9.2 Aqemia Business Overview
11.9.3 Aqemia AI-driven Drug Discovery Introduction
11.9.4 Aqemia Revenue in AI-driven Drug Discovery Business (2019-2024)
11.9.5 Aqemia Recent Development
11.10 Zephyr AI
11.10.1 Zephyr AI Company Detail
11.10.2 Zephyr AI Business Overview
11.10.3 Zephyr AI AI-driven Drug Discovery Introduction
11.10.4 Zephyr AI Revenue in AI-driven Drug Discovery Business (2019-2024)
11.10.5 Zephyr AI Recent Development
11.11 Cyclicarx
11.11.1 Cyclicarx Company Detail
11.11.2 Cyclicarx Business Overview
11.11.3 Cyclicarx AI-driven Drug Discovery Introduction
11.11.4 Cyclicarx Revenue in AI-driven Drug Discovery Business (2019-2024)
11.11.5 Cyclicarx Recent Development
11.12 Eli Lilly
11.12.1 Eli Lilly Company Detail
11.12.2 Eli Lilly Business Overview
11.12.3 Eli Lilly AI-driven Drug Discovery Introduction
11.12.4 Eli Lilly Revenue in AI-driven Drug Discovery Business (2019-2024)
11.12.5 Eli Lilly Recent Development
11.13 Terray Therapeutics
11.13.1 Terray Therapeutics Company Detail
11.13.2 Terray Therapeutics Business Overview
11.13.3 Terray Therapeutics AI-driven Drug Discovery Introduction
11.13.4 Terray Therapeutics Revenue in AI-driven Drug Discovery Business (2019-2024)
11.13.5 Terray Therapeutics Recent Development
11.14 Ardigen
11.14.1 Ardigen Company Detail
11.14.2 Ardigen Business Overview
11.14.3 Ardigen AI-driven Drug Discovery Introduction
11.14.4 Ardigen Revenue in AI-driven Drug Discovery Business (2019-2024)
11.14.5 Ardigen Recent Development
11.15 ReviveMed
11.15.1 ReviveMed Company Detail
11.15.2 ReviveMed Business Overview
11.15.3 ReviveMed AI-driven Drug Discovery Introduction
11.15.4 ReviveMed Revenue in AI-driven Drug Discovery Business (2019-2024)
11.15.5 ReviveMed Recent Development
11.16 Insilico Medicine
11.16.1 Insilico Medicine Company Detail
11.16.2 Insilico Medicine Business Overview
11.16.3 Insilico Medicine AI-driven Drug Discovery Introduction
11.16.4 Insilico Medicine Revenue in AI-driven Drug Discovery Business (2019-2024)
11.16.5 Insilico Medicine Recent Development
11.17 XtalPi
11.17.1 XtalPi Company Detail
11.17.2 XtalPi Business Overview
11.17.3 XtalPi AI-driven Drug Discovery Introduction
11.17.4 XtalPi Revenue in AI-driven Drug Discovery Business (2019-2024)
11.17.5 XtalPi Recent Development
11.18 MindRank
11.18.1 MindRank Company Detail
11.18.2 MindRank Business Overview
11.18.3 MindRank AI-driven Drug Discovery Introduction
11.18.4 MindRank Revenue in AI-driven Drug Discovery Business (2019-2024)
11.18.5 MindRank Recent Development
11.19 DP Technology
11.19.1 DP Technology Company Detail
11.19.2 DP Technology Business Overview
11.19.3 DP Technology AI-driven Drug Discovery Introduction
11.19.4 DP Technology Revenue in AI-driven Drug Discovery Business (2019-2024)
11.19.5 DP Technology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Entos
Selvita
Benevolent
Exscientia
Euretos
Illumina with AstraZeneca
Novo Nordisk with Microsoft
Iktos
Aqemia
Zephyr AI
Cyclicarx
Eli Lilly
Terray Therapeutics
Ardigen
ReviveMed
Insilico Medicine
XtalPi
MindRank
DP Technology

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.